---
title: "Barclays Remains a Buy on Madrigal Pharmaceuticals (MDGL)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276539913.md"
description: "Barclays analyst Eliana Merle has maintained a Buy rating on Madrigal Pharmaceuticals (MDGL) with a price target of $964.00, while the shares closed at $435.01. The analyst consensus is a Strong Buy with an average price target of $694.90, indicating a 59.74% upside. Truist Financial also reiterated a Buy rating with a $640.00 price target. Merle has a 4-star rating with a 43.33% success rate in the Healthcare sector."
datetime: "2026-02-22T12:16:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276539913.md)
  - [en](https://longbridge.com/en/news/276539913.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276539913.md)
---

# Barclays Remains a Buy on Madrigal Pharmaceuticals (MDGL)

Barclays analyst Eliana Merle maintained a Buy rating on Madrigal Pharmaceuticals on February 20 and set a price target of $964.00. The company’s shares closed last Friday at $435.01.

### President's Day Sale - 70% Off

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Merle is a 4-star analyst with an average return of 4.9% and a 43.33% success rate. Merle covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Alnylam Pharma, and Madrigal Pharmaceuticals.

Currently, the analyst consensus on Madrigal Pharmaceuticals is a Strong Buy with an average price target of $694.90, representing a 59.74% upside. In a report released on February 20, Truist Financial also reiterated a Buy rating on the stock with a $640.00 price target.

### Related Stocks

- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [MDGL.US](https://longbridge.com/en/quote/MDGL.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [BUZZ-Organon jumps on report of $12 bln buyout bid](https://longbridge.com/en/news/282320150.md)
- [BRIEF-Supernus Pharmaceuticals Inc Enters Asset Purchase Agreement With Navitor On April 1, 2026](https://longbridge.com/en/news/281936641.md)
- [Novo Nordisk's stock rallies after drugmaker reveals deal with OpenAI](https://longbridge.com/en/news/282698267.md)
- [Toth Financial Advisory Corp Makes New $1.17 Million Investment in Madrigal Pharmaceuticals, Inc. $MDGL](https://longbridge.com/en/news/281684693.md)
- [Pancreatic cancer pill shown to nearly double overall survival time, drug company says](https://longbridge.com/en/news/282687539.md)